Interestingly, our finding suggested the involvement of the proteasome inhibitor-Bortezomib in both canonical NF-κB and MAPK/p38 signaling pathways, highlighting TNFRSF13B as a big player in S100A9-associated myeloma progression. This evidence concerns the gene TNFRSF13B and plasma cell myeloma.